Sir,
Autoimmune pulmonary alveolar proteinosis (PAP) is caused by an autoantibody against granulocyte macrophage colony-stimulating factor (GM-CSF). 1 We previously reported a case of autoimmune PAP associated with systemic lupus erythematosus (SLE) in which immunosuppressive therapy worsened the PAP and reduction of the therapeutic dose improved it. 2 Here, we report a follow-up of the clinical course of this patient and show how we were able to control PAP exacerbation.
A 26-year-old Japanese woman was diagnosed with SLE because of photosensitivity, malar rash, arthritis, thrombocytopenia and positivity for ANA and anti-RNP antibody, although anti-DNA, Sm, Ro, La and cardiolipin antibodies were negative and complement levels were within the normal range. Two months later, she presented with a cough and dyspnea on exertion. Chest radiography revealed patchy alveolar infiltrates. She was diagnosed as having interstitial pneumonia associated with SLE and was treated with high dose glucocorticoid (GC), cyclosporine and intravenous cyclophosphamide. However, her respiratory symptoms and the chest infiltrates worsened. She was then transferred to our hospital. Further diagnostic work-up revealed crazy-paving pattern on computed tomography, milky broncho-alveolar lavage fluid, pathologic findings of alveoli filled with eosinophilic material and positive serum anti-GM-CSF antibody. Based on these findings, the patient was diagnosed with autoimmune PAP. Because of a coexistent fungal infection, immunosuppressant agents were stopped and the dose of GC was tapered, which improved the respiratory symptoms and chest infiltrates. 2 Six months after admission to our hospital, the patient had recurrent cough and dyspnea with progression of chest infiltrates. An exacerbation of PAP was considered. Her symptoms could be temporarily improved by whole lung lavage (WLL), but would recur and worsen 1-3 months after every WLL. Despite repeated WLL, her respiratory condition gradually progressed and she required continuous oxygen inhalation. Two years after starting WLL when the SLE and fungal infection was controlled with prednisolone (8 mg/day), four doses of rituximab (365 mg/m 2 ) were given which depleted CD19þ cells (<0.1%) in the peripheral blood without reduction of immunoglobulin levels four weeks after starting rituximab. Rituximab improved her respiratory condition and chest infiltrates (Figure 1 ). Six months after rituximab infusion, she was able to return to her work and the activities of daily living, without the need for oxygen inhalation. The SLE remained controlled well without changes in serum levels of complement, CRP or autoantibodies. To the best of our knowledge, this is the first report that shows the efficacy of rituximab for connective tissue disease (CTD)-associated PAP.
We used enzyme-linked immunosorbent assay to determine the serum anti-GM-CSF antibody levels after rituximab therapy. As shown in Table 1 , the serum anti-GM-CSF antibody level was not decreased by rituximab. To assess the neutralizing activity of the GM-CSF antibody, we examined its inhibitory effect on neutrophil CD11b expression 3 and found that the serum samples had neutralizing activity before and after rituximab therapy. Therefore, we deduced that rituximab improved PAP without decreasing the levels of neutralizing anti-GM-CSF antibody. Similar findings have been reported; however, some authors showed that the antibody levels in the lungs were decreased. 4 Taken together, rituximab may improve autoimmune PAP through unknown mechanisms other than decreasing autoantibody levels. We hypothesize the mechanism to be modification of the function of lymphocytes and/or macrophages that cause PAP, but further studies are needed to substantiate this.
Nevertheless, rituximab could be a promising therapy for autoimmune PAP associated with CTDs, although the mechanism remains unknown. 
the neutralizing activity of anti-GM-CSF antibody was examined through inhibition of neutrophil CD11b expression. Neutrophils from healthy donors were incubated with GM-CSF (5 ng/ml) and serum from the subjects at a final dilution of 1:20 (v/v). After 20 minutes of incubation at 37 C, CD11b expression on neutrophils was examined using flow cytometry. c Five serum samples from healthy controls were examined and no samples had neutralizing activity for GM-CSF. GM-CSF; granulocyte macrophage colony-stimulating factor; OD: optical density; PAP: pulmonary alveolar proteinosis.
